Skip to main content
. Author manuscript; available in PMC: 2020 Mar 1.
Published in final edited form as: Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Dec 20;1864(3):358–371. doi: 10.1016/j.bbalip.2018.12.012

Fig. 9.

Fig. 9.

Repression of ACSL1 mRNA expression by FXR agonists in mouse and human primary hepatocytes.

(A) MPHs were treated with GW4064 (1 μM) and OCA (10 μM) for 24 h before isolation of total RNA. Triplicate wells were used in each condition. qRT-PCR was performed to measure relative mRNA levels of indicated genes with triplicate measurement of each cDNA sample.

(B) HPHs were treated with FXR agonists at indicated concentrations for 24 h before isolation of total RNA. Duplicate wells were used in each condition and qRT-PCR was performed to measure ACSL1 and GAPDH mRNA levels with triplicate measurement of each cDNA sample.

Statistical significance was determined with One-way ANOVA with Dunnett’s Multiple Comparison posttest. ***p value < 0.001 compared to the DMSO control.